Search this site
Navigation
Home
About Us
Latest Medication News
UMMC On-line Formulary Version 2
Our Services
Pharmacy Guidelines & References
UMMC On-line Antibiotic Guideline
UMMC Pediatric Dosing Guide & Manual
UMMC Algorithm for Pharmacological Management of MDD
Other Pharmacy Guidelines & References
Antidotes & Antidotes Kit
Aspirin Desensitisation Protocol
Dilution Protocols
Extemporaneous Preparations
High Alert Medications
Tutorial Videos
UMMC Intravenous Drip Preparation
Prescriber's Handbook
Drug & Therapeutics Subcommittee
Medication Sampling Procedure
Medication Supply Procedures
After Office Hours & Emergency Request
Carbapenem Antibiotics Request
Chemotherapy Agents Request
Parenteral Nutrition (PN) Request
Supply of Anti-Retrovirals for Prophylaxis
MTAC- Warfarin (Ministry of Health)
Off-label Medication Use Consent Form
Therapeutic Drug Monitoring (TDM)
Patient's Handbook
Achievements & Events
Contact Us
FAQ
6
days until
Thaipusam
Useful Links
About Us
>
Latest Medication News
>
Medication Brand Conversion - Gabapentin
posted
Mar 8, 2017, 5:06 PM
by Chong Ching Wern
[ updated
Mar 8, 2017, 5:06 PM
by Ho Ai Wui ]
8th March 2017 (Circular No. SP PPUM: 94/2017):
Ummc will soon be supplying patients who are on Gabapentin 300 mg to the following:
Brand:
Gabenil 300
Form:
Capsule
Colour:
Yellow
Company:
Remedica Ltd.
It will be replacing the Neurontin Capsules by Pfizer.
Gabapentin 300 mg Capsules (Gabenil 300)